Nancy Chan

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Matteo Palmeri, Janice M. Mehnert, Ann W. Silk et al. · ESMO Open · 2021 · 333 citations · Full text

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research · 2019 · 237 citations · Full text

Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases

Nancy Chan, Amy D. Willis, Naomi Kornhauser et al. · Clinical Cancer Research · 2016 · 216 citations

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Anshuman Panda, Janice M. Mehnert, Kim M. Hirshfield et al. · JNCI Journal of the National Cancer Institute · 2017 · 213 citations · Full text

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

Mark N. Stein, Joseph R. Bertino, Howard L. Kaufman et al. · Clinical Cancer Research · 2017 · 153 citations · Full text